Tag Archives: Xeljanz
-
-
Drugs Advertised on TV Often Have Low Therapeutic Value, Study Finds
Harvard researchers warn that drug companies spend billions of dollars advertising medications which are not as effective, and often more expensive, than other options, researchers warn.
-
EMA Calls for Restricted Use of Xeljanz, Rinvoq, Similar Drugs Due to Heart, Cancer, Blood Clot and Infection Risks
European regulators urge doctors to limit the use of Xeljanz and similar drugs among certain patients more prone to heart problems and blood clots.
-
Study Questions Whether Side Effects of Xeljanz, Similar Drugs, Increase Blood Clot Risks
A new study raises doubts about whether Xeljanz and similar drugs increase the risk of blood clots.
-
Xeljanz Infection Risk Higher Than TNF Inhibitors: Study
Xeljanz use carries a higher infection risk than other arthritis drugs, like Humira, according to the findings of a new study.
-
Skin Cancer Risk Linked to Xeljanz, Jakafi, Other JAK Inhibitors: Study
A new study links Xeljanz and similar drugs to an increased risk of skin cancer.
-
Rinvoq Lawsuit Filed Against AbbVie By Investors Over Failure to Disclose Safety Concerns
AbbVie faces a class action lawsuit by investors who say the company mislead them about the safety of Rinvoq before new warning labels for cancer and heart problems were added.
-
Xeljanz Stroke Lawsuit Filed Against Pfizer for Gross Negligence in Failing to Warn About Drug Risks
A Xeljanz stroke lawsuit claims Pfizer failed to adequately warn about the drug's heart risks.
-
Xeljanz Lawsuit Filed Over Failure to Warn About Risk of Blood Clots, Pulmonary Embolisms
A Xeljanz lawsuit claims Pfizer misled the public about the safety of the rheumatoid arthritis drug, leading to a man suffering a life-threatening blood clot.
-
Makers of Oluminant Withdraw Lupus Treatment Approval Request in Face of JAK-Inhibitor Health Risks
A request for approval for Olumiant to treat lupus has been withdrawn, and the manufacturers expect the FDA to reject an atopic dermatitis approval request in the face of growing…
